At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 9 target
Drug / intervention
Low Dose DCSZ11 +3 moredrug
Likely dose
Low Dose DCSZ11 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Single-Arm Clinical Trial Evaluating DCSZ11 Combined With Standard-of-Care Therapy in Patients With Advanced or Metastatic Solid Tumors
In Brief
A Phase 2 clinical trial evaluating Low Dose DCSZ11, Medium Dose DCSZ11, and 2 other interventions for DCSZ11 and 2 related conditions. Currently recruiting, targeting 9 participants across 1 site.
Detailed Summary
To evaluate the safety and efficacy of DCSZ11 in combination with standard therapy in patients with advanced or metastatic solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDCSZ11, Solid Tumors, HNSCC
CountriesChina
Collaborators--
Timeline
Phase 2Recruiting
20262027
First PostedJun 2025
Enrollment StartDec 2025
TodayJul 2026
Primary CompletionJun 2027
Study CompletionJul 2027
First PostedJun 25, 2025
Enrollment StartDec 16, 2025
Primary CompletionJun 1, 2027
Study CompletionJul 30, 2027
TodayJul 1, 2026
Enrollment to primary: 1.5 yearsPosted 1.0 years agoPrimary completion in 11 months
Interventions
Low Dose DCSZ11drug
Patients will receive DCSZ11 at 600 mg every three weeks (Q3W).
Medium Dose DCSZ11drug
Patients will receive DCSZ11 at 800 mg Q3W.
High Dose DCSZ11drug
Patients will receive DCSZ11 at 1200 mg Q3W.
Standard Treatmentdrug
The available standard treatment for head and neck cancer patients.